ACCC publishes white paper on integrated health care systems

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE ASSOCIATION OF COMMUNITY CANCER CENTERS published a white paper, titled “What Will It Take? Five Essential Actions to Achieve a Positive Impact on Patient Care in the Integrated Healthcare Environment,” at its 32nd National Oncology Conference, addressing patient care in a changing provider setting.

The five actions described in the white paper are: aligning stakeholders and requiring accountability; defining quality in a value-based reimbursement system and providing access to quality care; using non-traditional delivery systems such as telehealth and primary care physicians and non-physician providers to deliver cancer care; integrating the use of big data to drive treatment decisions; and moving to patientdirected care in which the patient is at the center of all decisions and systemic change.

“Increased integration will impact all aspects of an organization’s cancer care delivery — cultural, operational, clinical and financial,” said ACCC President Steven D’Amato. “Our focus in this newly integrated environment is to provide education for hospital systems and physician practices on how to offer the best collaborative oncology care in a seamless way for patients.”

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login